Research and Markets: Worldwide Nasopharyngitis (Common Cold) - Pipeline Review, H2 2013

Research and Markets (http://www.researchandmarkets.com/research/cwz9jd/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H2 2013" report to their offering.

'Nasopharyngitis (Common Cold) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngitis (Common Cold), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold).

Scope

• A snapshot of the global therapeutic scenario for Nasopharyngitis (Common Cold).
• A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Nasopharyngitis (Common Cold) pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Companies Mentioned

• Hydra Biosciences, Inc.
• Tris Pharma, Inc.
• Neos Therapeutics, Inc.

Drug Profiles

• TRPM8 Antagonist
• CCP-06
• CCP-07
• CCP-05
• CCP-08
• Compound-89
• Drug For Cough/Cold
• TRIM-21 Targeting Antibody
• Nitric Oxide Therapy
• CCP-3 Program
• CCP-01
• CCP-2
• CCP-4

For more information visit http://www.researchandmarkets.com/research/cwz9jd/nasopharyngitis

Research and Markets
Laura Wood, Senior Manager.
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Pharmaceuticals